Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
20.94
-0.60 (-2.79%)
At close: May 13, 2025, 4:00 PM
20.27
-0.67 (-3.18%)
Pre-market: May 14, 2025, 8:57 AM EDT
Travere Therapeutics Employees
Travere Therapeutics had 385 employees as of December 31, 2024. The number of employees increased by 5 or 1.32% compared to the previous year.
Employees
385
Change (1Y)
5
Growth (1Y)
1.32%
Revenue / Employee
$710,475
Profits / Employee
-$588,857
Market Cap
1.86B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TVTX News
- 1 day ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 days ago - Travere Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 12 days ago - Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Travere Therapeutics Reports First Quarter 2025 Financial Results - Business Wire
- 15 days ago - Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy - Business Wire
- 15 days ago - CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - PRNewsWire
- 19 days ago - Travere Therapeutics to Report First Quarter 2025 Financial Results - Business Wire
- 6 weeks ago - Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 - Business Wire